Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC
In this large cohort study of patients with R/M HNSCC receiving ICI-based therapy, survival estimates closely mirrored clinical trial results, both in frontline and later-line settings. Discontinuation of ICI in long-term responders at 1 or 2 years may be a reasonable strategy that does not appear to compromise survival. ICI rechallenge was associated with clinical benefit in a subset of patients.
Authors
- Lova Sun (ORCID: https://orcid.org/0000-0002-5015-2964)
- Jonathan D. Schoenfeld (ORCID: https://orcid.org/0000-0002-5119-0401)
- Christopher D’Avella (ORCID: https://orcid.org/0000-0003-2276-0257)
- Aditi Singh (ORCID: https://orcid.org/0000-0001-7438-2863)
- Glenn J. Hanna (ORCID: https://orcid.org/0000-0003-3870-8330)
- Roger B. Cohen
Institutions
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.28526
- Citations
- 21
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 12.18